Lipigon Pharmaceuticals (LPGO) Study Result summary

Study design and objectives

• Phase II randomized, placebo-controlled trial included 23 patients with moderate to severe hypertriglyceridemia.

• Patients received four weekly doses and were followed for 12 weeks, with a 6-month long-term follow-up planned.

• Primary objective was to assess safety and tolerability; secondary objectives included effects on triglycerides, remnant cholesterol, and insulin resistance.

Key results and findings

• Lipisense® was found to be safe and well tolerated, with no serious treatment-related adverse events.

• No clinically relevant reduction in triglyceride or remnant cholesterol levels was observed compared to placebo.

• A trend toward decreased insulin resistance was noted in the treatment group.

• No statistically significant efficacy signals for lipid markers were detected.

Next steps and future outlook

• Detailed analysis of the results is ongoing to determine the future direction of the development project.

• Complete results, including long-term follow-up data, are expected in 2026.

• The company aims to establish a global licensing agreement for Lipisense®.